AstraZeneca raises bet on Japan by buying out Sumitomo
LONDON (Reuters) - AstraZeneca (AZN.L) has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical (4005.T) in its Japanese unit AstraZeneca K.K.
The British group said on Wednesday the purchase of the shares cost approximately 10 billion yen ($102 million) and reinforced its focus on Japan as a key growth platform.
Japan, the world's second-largest pharmaceuticals market after the United States, is an increasingly important country for Western drugmakers.
In the past, it has been a tough market for foreign drug firms to crack, but recent steps to speed up the approval process have opened the door to a raft of commercially important drugs.
LONDON - Risk appetite flickered back into life in financial markets on Tuesday with the dollar and European and Japanese shares rising while safe-haven bonds, the yen and gold all took a step back.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.